[Durgical](https://durgical.com/en/) › [DurgiPedia](https://durgical.com/en/durgipedia/) › [Pharmacology](https://durgical.com/en/pharmacology/) › [PCSK9 inhibitors](https://durgical.com/en/pharmacology/classes/pcsk9-inhibitors/) › Inclisiran # Inclisiran ## PCSK9 inhibitors? PCSK9 inhibitors A small interfering RNA injected under the skin twice a year after the first doses; it silences the liver's PCSK9 gene and lowers LDL cholesterol. Updated Nov 1, 2026 ## Quick facts **Group** [PCSK9 inhibitors](https://durgical.com/en/pharmacology/classes/pcsk9-inhibitors/) **Target** PCSK9 messenger RNA in liver cells (blocks PCSK9 protein synthesis) **Used for** High LDL cholesterol in adults **Key effects** Injection-site pain · Joint pain **Monitor** Injection-site reactions · Signs of allergy **ATC** C10AX16 No doses: the clinician sets them by the current guideline. On this page - The basics Mechanism of action - Indications - Adverse effects - Pharmacokinetics - Memory aid - Safety Contraindications - Key interactions - What is monitored - Administration and safety - Pregnancy and breastfeeding - Nursing care - Study Test yourself - Connections Connections ## Mechanism of action Inclisiran is a double-stranded small interfering RNA (siRNA) linked to a sugar (N-acetylgalactosamine) that hepatocytes take up through the asialoglycoprotein receptor. Inside the cell it loads into the RNA-induced silencing complex and guides cleavage of PCSK9 messenger RNA. Less PCSK9 protein is made, fewer LDL receptors are destroyed, more receptors recycle to the cell surface and LDL cholesterol falls for months. - Sugar-tagged siRNA is taken up by liver cells - Guides the cell's silencing complex to cut PCSK9 mRNA - Less PCSK9 protein; LDL receptors are spared - More LDL removed from the blood for months ## Indications - High LDL cholesterol in adults with atherosclerotic cardiovascular disease, added to diet and maximally tolerated statin [Atherosclerosis and dyslipidaemia →](https://durgical.com/en/conditions/atherosclerosis-and-dyslipidaemia/) - Heterozygous familial hypercholesterolaemia needing extra LDL lowering [Familial hypercholesterolemia →](https://durgical.com/en/conditions/familial-hypercholesterolemia/) ## Adverse effects ### Common - Injection-site pain, swelling or redness - Joint pain - Bronchitis-like symptoms: cough, wheeze, shortness of breath ### Serious (rare, important) - Allergic reactions (rash, hives, swelling of face or throat, breathing difficulty) ## Contraindications - Hypersensitivity to inclisiran ## Key interactions **Statins and ezetimibe** LDL lowering adds up; inclisiran is used on top of them. ## What is monitored - LDL cholesterol after the first doses and then periodically - Injection-site reactions - Signs of allergy ## Administration and safety - Subcutaneous injection in the abdomen, upper arm or thigh, given by a health professional. - After the first dose and a second one three months later, it is given every six months; a missed dose may require restarting the schedule. - Not injected into skin that is inflamed, bruised or scarred. - Inclisiran (siRNA) is not the same as PCSK9 antibodies (alirocumab, evolocumab) despite the shared target. ## Pregnancy and breastfeeding Not recommended: there are few data and the drug lowers cholesterol, which the fetus needs; it is usually stopped when pregnancy is found. ## Nursing care - Before: allergy history, current lipid-lowering drugs. - During: inspect the injection site and watch for allergic reactions. - Record the date of each dose and schedule the next one. - Teach that statins and diet continue. ## Pharmacokinetics **Absorption** Subcutaneous injection; taken up quickly and selectively by the liver. **Onset and duration** LDL falls within about two weeks of a dose and the effect lasts for months, which allows dosing twice a year after the first doses (G&G). ## Memory aid IncliSIRAN = siRNA: it 'whispers' to the liver to stop making PCSK9. Antibodies (-mabs) grab the protein; inclisiran stops it being made. Two shots a year, given by staff. ## Test yourself Think of the answer, then tap the question to see it. ## How does inclisiran's mechanism differ from evolocumab's? Evolocumab is an antibody that binds circulating PCSK9 protein; inclisiran is an siRNA that stops PCSK9 being made in the liver. ## Why does inclisiran reach the liver so selectively? It carries an N-acetylgalactosamine sugar that hepatocyte asialoglycoprotein receptors take up. ## What is the most frequent adverse effect of inclisiran? Injection-site reactions. [Add to my cards (3)](https://durgical.app/estudiar/?add=/en/pharmacology/inclisiran/) [More Pharmacology questions →](https://durgical.com/en/practice/?f=pharmacology) ## Connections ## Related drugs 2 - [Evolocumab](https://durgical.com/en/pharmacology/evolocumab/) - [Alirocumab](https://durgical.com/en/pharmacology/alirocumab/) ## Related conditions 2 - [Atherosclerosis and dyslipidaemia](https://durgical.com/en/conditions/atherosclerosis-and-dyslipidaemia/) - [Familial hypercholesterolemia](https://durgical.com/en/conditions/familial-hypercholesterolemia/) [← Back to the class: PCSK9 inhibitors](https://durgical.com/en/pharmacology/classes/pcsk9-inhibitors/) Educational content on how drugs work; not a prescribing guide and no substitute for a health professional's advice. No doses are given. Sources: [Inclisiran injection: MedlinePlus Drug Information](https://medlineplus.gov/druginfo/meds/a622009.html) (MedlinePlus (U.S. National Library of Medicine), 2026); [ATCDDD - ATC/DDD Index](https://atcddd.fhi.no/atc_ddd_index/?code=C10AX16) (WHO Collaborating Centre for Drug Statistics Methodology, 2026). ## **Spotted a mistake?** We are always improving for the community. Tell us what is wrong and our team will review it. Report a mistake Representative model, for educational purposes only. --- Source: https://durgical.com/en/pharmacology/inclisiran/ License: CC BY 4.0 (https://creativecommons.org/licenses/by/4.0/). Cite as: DurgiPedia (durgical.com), https://durgical.com/en/pharmacology/inclisiran/